高级别浆液性卵巢癌CT纹理异质性与预后及BRCA突变状态的相关性
回顾性纳入88例高级别浆液性卵巢癌患者,分析CT纹理异质性参数与总生存、无进展生存及BRCA突变状态的关系。结果显示较高的异质性参数与较差的无进展生存和总生存相关,且在BRCA阴性患者中与手术完全切除率较低相关,但无法区分BRCA突变状态。
要点
- CT纹理异质性参数(SCV、SCP、SE)升高与高级别浆液性卵巢癌患者无进展生存和总生存降低相关。
- 在BRCA阴性患者中,SCV、SCP、SE升高与手术完全切除率较低相关;BRCA阳性患者中无此关联。
- CT纹理异质性参数无法区分BRCA突变携带者与非携带者。
核心结论
- 高级别浆液性卵巢癌的CT纹理异质性参数升高与较差的无进展生存、总生存及BRCA阴性患者手术完全切除率较低相关,但无法评估BRCA突变状态。
研究设计与样本
- 回顾性研究,纳入88例接受初次肿瘤细胞减灭术前CT检查和BRCA突变状态检测的高级别浆液性卵巢癌患者。
关键影像表现/征象
- 较高的病灶间聚类方差(SCV)与较低的无进展生存(p=0.006)和总生存(p=0.003)相关。
- 较高的病灶间聚类突出度(SCP)与较低的无进展生存(p=0.02)相关。
- 较高的病灶间聚类熵(SE)与较低的总生存(p=0.01)相关。
诊断标准与关键数值
- SCV、SCP、SE在BRCA阴性患者中升高均与手术完全切除率较低显著相关(SE p=0.039,SCV p=0.006,SCP p=0.02),在BRCA阳性患者中无显著相关(SE p=0.7,SCV p=0.91,SCP p=0.67)。
- SCV、SCP、SE均不能区分BRCA突变携带者与非突变携带者。
临床应用与阅片要点
- 使用标准治疗CT扫描的放射组学方法可能提供无创工具预测高级别浆液性卵巢癌患者预后,从而改善治疗效果。
- CT纹理异质性参数在BRCA阴性患者中与手术完全切除率相关,但在BRCA阳性患者中无此关联。
- CT纹理异质性参数无法用于评估BRCA突变状态。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To assess the associations between inter-site texture heterogeneity parameters derived from computed tomography (CT), survival, and BRCA mutation status in women with high-grade serous ovarian cancer (HGSOC).
MATERIALS AND METHODS: Retrospective study of 88 HGSOC patients undergoing CT and BRCA mutation status testing prior to primary cytoreductive surgery. Associations between texture metrics-namely inter-site cluster variance (SCV), inter-site cluster prominence (SCP), inter-site cluster entropy (SE)-and overall survival (OS), progression-free survival (PFS) as well as BRCA mutation status were assessed.
RESULTS: Higher inter-site cluster variance (SCV) was associated with lower PFS (p = 0.006) and OS (p = 0.003). Higher inter-site cluster prominence (SCP) was associated with lower PFS (p = 0.02) and higher inter-site cluster entropy (SE) correlated with lower OS (p = 0.01). Higher values of all three metrics were significantly associated with lower complete surgical resection status in BRCA-negative patients (SE p = 0.039, SCV p = 0.006, SCP p = 0.02), but not in BRCA-positive patients (SE p = 0.7, SCV p = 0.91, SCP p = 0.67). None of the metrics were able to distinguish between BRCA mutation carrier and non-mutation carrier.
CONCLUSION: The assessment of tumoral heterogeneity in the era of personalized medicine is important, as increased heterogeneity has been associated with distinct genomic abnormalities and worse patient outcomes. A radiomics approach using standard-of-care CT scans might have a clinical impact by offering a non-invasive tool to predict outcome and therefore improving treatment effectiveness. However, it was not able to assess BRCA mutation status in women with HGSOC.
引用
- Meier A, Veeraraghavan H, Nougaret S, et al. Association between CT-texture-derived tumor heterogeneity, outcomes, and BRCA mutation status in patients with high-grade serous ovarian cancer. Abdom Radiol (NY). 2019. PMID: 30474722. doi:10.1007/s00261-018-1840-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。